P. Ballard

发表

Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.

A. Rabow, D. M. Andrews, G. Walker, 2015, Journal of medicinal chemistry.

Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.

Peter Ballard, Simon J Brown, Nathaniel G. Martin, 2014, Journal of medicinal chemistry.

Chapter 10 – Metabolism and pharmacokinetic optimization strategies in drug discovery

P. Ballard, K. Bui, P. Brassil, 2013 .

Prediction of in Vivo Tissue Distribution from in Vitro Data. 2. Correlation Between in Vitro and in Vivo Tissue Distribution of a Homologous Series of Nine 5-n-Alkyl-5-Ethyl Barbituric Acids

M. Rowland, D. Leahy, P. Ballard, 2003, Pharmaceutical Research.

Determination of microsome and hepatocyte scaling factors for in vitro/in vivo extrapolation in the rat and dog

P. Ballard, R. Smith, R. Jones, 2008, Xenobiotica; the fate of foreign compounds in biological systems.

Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor

P. Ballard, P. Dickinson, M. Cantarini, 2016, Drug Metabolism and Disposition.

Title Page Metabolic Disposition of Osimertinib in Rat , Dog , and Man : insights into a drug designed to bind covalently to a cysteine residue of EGFR

P. Ballard, P. Dickinson, M. Cantarini, 2016 .

Running title : Pharmacology of SERD inhibitor in breast cancer models

Graham, A. Rabow, R. A. Norman, 2016 .

Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer.

A. Rabow, D. M. Andrews, G. Walker, 2011, Bioorganic & medicinal chemistry letters.

Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket.

Andrew G. Leach, Paul D. Johnson, R. Morgentin, 2006, Bioorganic & medicinal chemistry letters.

Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors.

Peter D Smith, J. Kendrew, Rebecca P A Ellston, 2006, Bioorganic & medicinal chemistry letters.

Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket.

Paul D. Johnson, R. Morgentin, R. Bradbury, 2006, Bioorganic & medicinal chemistry letters.

5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase.

Paul D. Johnson, R. Morgentin, R. Bradbury, 2005, Bioorganic & medicinal chemistry letters.

A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.

James S. Scott, B. Barlaam, R. Ducray, 2008, Bioorganic & medicinal chemistry letters.

Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.

James S. Scott, B. Barlaam, R. Bradbury, 2007, Bioorganic & Medicinal Chemistry Letters.

Novel 3‐Alkoxy‐1H‐pyrazolo[3,4‐d]pyrimidines as EGFR and erbB2 Receptor Tyrosine Kinase Inhibitors.

B. Barlaam, R. Ducray, P. Ballard, 2008 .

Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors.

Peter Ballard, Jason G. Kettle, B. Barlaam, 2008, Bioorganic & medicinal chemistry letters.

The development and performance of a radioimmunoassay for the analysis of ZM 213,689, the major metabolite of meropenem--a carbapenem antibiotic--in plasma and urine.

P. Ballard, B. Law, L. E. Stafford, 1996, Journal of pharmaceutical and biomedical analysis.

The use of competitive displacement agents to resolve albumin binding problems observed during the development of a radioimmunoassay for ICI 215001.

P. Ballard, B. Law, M. Malone, 1994, Journal of pharmaceutical and biomedical analysis.

Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.

Peter Ballard, Andrew G. Leach, Jason G Kettle, 2013, Journal of medicinal chemistry.

Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.

J. Kendrew, R. Bradbury, P. Ballard, 2006, Bioorganic & medicinal chemistry letters.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

William Pao, Peter Ballard, Hailing Jin, 2014, Cancer discovery.

Development, Verification, and Prediction of Osimertinib Drug–Drug Interactions Using PBPK Modeling Approach to Inform Drug Label

Peter Ballard, Venkatesh Pilla Reddy, P. Ballard, 2018, CPT: pharmacometrics & systems pharmacology.

Prediction of In Vivo Tissue Distribution from In Vitro Data 1. Experiments with Markers of Aqueous Spaces

Peter Ballard, Malcolm Rowland, David E. Leahy, 2000, Pharmaceutical Research.

The right compound in the right assay at the right time: an integrated discovery DMPK strategy

Peter Ballard, Patrick Brassil, Khanh H Bui, 2012, Drug metabolism reviews.

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

Matthew Grist, P. Jänne, K. Varnäs, 2016, Clinical Cancer Research.

Development of an assay for the extraction and quantification of nine 5-n-alkyl-5-ethyl barbituric acids in various rat tissues.

M. Rowland, D. Leahy, P. Ballard, 1999, Journal of Pharmaceutical and Biomedical Analysis.

Correction for Nonspecific Binding to Various Components of Ultrafiltration Apparatus and Impact on Estimating In Vivo Rat Clearance for a Congeneric Series of 5-Ethyl, 5-n-Alkyl Barbituric Acids

M. Rowland, P. Ballard, 2011, Drug Metabolism and Disposition.

Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man

P. Ballard, H. Swaisland, S. Ghiorghiu, 2014, Xenobiotica; the fate of foreign compounds in biological systems.

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.

A. Rabow, G. Walker, R. A. Norman, 2016, Cancer research.

Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic–Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104

Peter Ballard, James W T Yates, S. Ashton, 2016, Molecular Cancer Therapeutics.

Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivo.

Peter Ballard, Leonie Campbell, David Buttar, 2009, Bioorganic & medicinal chemistry letters.

Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis.

Mark Cockerill, J. Debreczeni, S. Guichard, 2015, Journal of medicinal chemistry.

An approach to the evaluation and comparison of reversed-phase high-performance liquid chromatography stationary phases.

P. Ballard, B. Law, S. J. Houghton, 1998, Journal of pharmaceutical and biomedical analysis.

456PPRECLINICAL EVIDENCE AND CLINICAL CASES OF AZD9291 ACTIVITY IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) BRAIN METASTASES (BM).

P. Janne, D. Cross, P. Ballard, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract DDT01-03: Discovery and pre-clinical pharmacology of AZD9496: An oral, selective estrogen receptor down-regulator (SERD)

A. Rabow, D. M. Andrews, G. Walker, 2015 .

Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.

B. Barlaam, R. Bradbury, P. Ballard, 2013, ACS medicinal chemistry letters.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

W. Pao, M. Ranson, Hailing Jin, 2014, Cancer discovery.

Azd9291, an Irreversible Egfr Tki, Overcomes T790m-mediated Resistance to Egfr Inhibitors in Lung Cancer Oncology Innovative Medicines And

W. Pao, D. Cross, R. Rowlinson, 2022 .

Metabolic Disposition of Osimertinib in Rat, Dog, and Man: insights into a drug designed to bind covalently to a cysteine residue of EGFR

P. Ballard, P. Dickinson, M. Cantarini, 2016 .

Prediction of in Vivo Tissue Distribution from in Vitro Data. 2. Influence of Albumin Diffusion from Tissue Pieces During an in Vitro Incubation on Estimated Tissue-to-Unbound Plasma Partition Coefficients (Kpu)

M. Rowland, D. Leahy, P. Arundel, 2003, Pharmaceutical Research.